Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion type Assertion NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_head.
- NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion description "[Embedded in this study was peripheral blood sampling for TMPRSS2-ERG and SPINK1, two genes that are believed to define prostate cancer genotypes, to assess their utility as biomarkers This study suggests that at the delivered doses, cytarabine has limited efficacy and significant myelotoxicity suggesting, it does not have a role in the treatment of docetaxel-refractory CRPC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_provenance.
- NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion evidence source_evidence_literature NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_provenance.
- NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion SIO_000772 22313860 NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_provenance.
- NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion wasDerivedFrom befree-20140225 NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_provenance.
- NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_assertion wasGeneratedBy ECO_0000203 NP504827.RAKYhfpHoDkqOiQeimoko4x_K2dBMKIFScwAuJpI8eiEI130_provenance.